Edwards Lifesciences Corporation (NYSE:EW) Shares Bought by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC lifted its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 26,909 shares of the medical research company's stock after buying an additional 7,283 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Edwards Lifesciences were worth $1,950,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $27,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $29,000. Global X Japan Co. Ltd. raised its position in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC lifted its holdings in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Piper Sandler increased their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Citigroup reissued a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Evercore ISI upped their price target on Edwards Lifesciences from $73.00 to $77.00 and gave the stock an "in-line" rating in a research note on Tuesday. Finally, Robert W. Baird lifted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $80.40.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer directly owned 41,098 shares in the company, valued at approximately $3,057,691.20. The trade was a 21.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,348 shares of company stock worth $2,977,683. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Up 1.1%

NYSE EW traded up $0.82 during trading on Wednesday, reaching $77.21. 2,635,589 shares of the company's stock were exchanged, compared to its average volume of 5,246,424. The company has a 50 day moving average price of $76.14 and a two-hundred day moving average price of $73.31. The stock has a market cap of $45.29 billion, a P/E ratio of 11.03, a price-to-earnings-growth ratio of 3.84 and a beta of 1.11. Edwards Lifesciences Corporation has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The business's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.66 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.